Drug Profile
EB 03
Alternative Names: EB-03Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Edesa Biotech
- Class Antihaemorrhagics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fissure in ano; Haemorrhoids
Most Recent Events
- 18 Sep 2023 Discontinued - Phase-I for Fissure in ano in Canada (Topical)
- 18 Sep 2023 Discontinued - Preclinical for Haemorrhoids in Canada (Rectal)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Haemorrhoids in Canada (Rectal)